Abatacept CTLA4lg; BMS-188667|cas:332348-12-6|西域试剂

Abatacept CTLA4lg; BMS-188667,99.0%

产品编号：Bellancom-108829| CAS NO：332348-12-6

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-108829		￥5500.00	杭州北京（现货）
Bellancom-108829		￥9800.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Abatacept CTLA4lg; BMS-188667

产品介绍

Abatacept (CTLA4lg) 是一种可溶性融合蛋白，由人 CTLA4 的胞外结构域和人 IgG1 Fc 部分的片段 (铰链，CH2 和 3 结构域) 组成。Abatacept 是选择性 T 细胞共刺激调节剂，也是一种用于自身免疫性疾病的蛋白活性分子。

生物活性

Abatacept (CTLA4lg) is a soluble fusion protein consisting of the extra-cellular domain of human CTLA4 and a fragment of the Fc portion of human IgG1 (hinge and CH2 and 3 domains). Abatacept is a selective T-cell co-stimulation modulator and a protein agent for the autoimmune diseases.

体外研究

体内研究

Abatacept reduces paw edema, and the SC Multiple-dose group shows significantly greater (t_obs = 2.50) paw edema reduction compared with the IV dose group.
Abatacept exhibits linear PK across the studied doses. The NCA clearance (CL) is 20.8 mL/day/kg, volume (V_ss) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.
Abatacept (oral; 10 mg/kg; every 2 days) reduces the proportion of activated T cells (CD44highCD62L–) and inhibits the up-regulation of ICOS and CD71 in homozygous DO11.10 RAG-2^–/–BALB/c (H-2d/d) mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Lewis rats (6-9 weeks old) with weights of 150-175 g
Dosage:	10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29
Administration:	IV or SC
Result:	Reduced paw edema, and the SC Multiple-dose group showed significantly greater (t_obs = 2.50) paw edema reduction compared with the IV dose group.

Animal Model:	Male Lewis rats (6-9 weeks old) with weights of 150-175 g
Dosage:	10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 (Pharmacokinetic Study)
Administration:	IV or SC
Result:	The NCA clearance (CL) is 20.8 mL/day/kg, volume (V_ss) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Lewis rats (6-9 weeks old) with weights of 150-175 g
Dosage:	10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29
Administration:	IV or SC
Result:	Reduced paw edema, and the SC Multiple-dose group showed significantly greater (t_obs = 2.50) paw edema reduction compared with the IV dose group.

Animal Model:	Male Lewis rats (6-9 weeks old) with weights of 150-175 g
Dosage:	10 mg/kg (IV), 20 mg/kg (SC single-dose), 20 mg/kg (SC Multiple-dose) on day 21 with 10 mg/kg SC doses on days 23, 25, 27, and 29 (Pharmacokinetic Study)
Administration:	IV or SC
Result:	The NCA clearance (CL) is 20.8 mL/day/kg, volume (V_ss) is 146 mL/kg, and bioavailability (F) of the SC dose dosing is 57.7%.